Tidal Investments LLC Has $3.64 Million Stock Holdings in Haleon PLC Sponsored ADR $HLN

Key Points

• Tidal Investments cut its Haleon stake by 66.6% in the second quarter, selling 779,210 shares and retaining 390,259 shares valued at approximately $3.64 million.
• Analyst sentiment remains mixed but leans positive: Haleon has an overall “Moderate Buy” rating, with Buy and Strong Buy recommendations offset by five Holds and one Sell.
• Haleon shares opened at $9.39, while the company announced a quarterly dividend of $0.0642 per share and has a 30.77% dividend payout ratio.

Tidal Investments LLC decreased its stake in Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) by 66.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 390,259 shares of the company's stock after selling 779,210 shares during the period. Tidal Investments LLC's holdings in Haleon were worth $3,641,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its stake in shares of Haleon by 17.0% in the 1st quarter. Bank of America Corp DE now owns 10,934,228 shares of the company's stock valued at $109,452,000 after acquiring an additional 1,586,230 shares during the last quarter. Goodman Financial Corp bought a new stake in Haleon during the 1st quarter worth $11,488,000. Public Employees Retirement System of Ohio grew its position in Haleon by 136.4% during the 1st quarter. Public Employees Retirement System of Ohio now owns 222,708 shares of the company's stock worth $2,229,000 after acquiring an additional 128,493 shares during the last quarter. Milford Funds Ltd. acquired a new position in Haleon in the 4th quarter worth about $1,820,000. Finally, Savant Capital LLC increased its holdings in Haleon by 249.5% in the 4th quarter. Savant Capital LLC now owns 113,228 shares of the company's stock worth $1,145,000 after purchasing an additional 80,831 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a "sell" rating on shares of Haleon in a research note on Wednesday, September 9th. Wall Street Zen upgraded shares of Haleon from a "hold" rating to a "buy" rating in a report on Sunday, July 12th. Zacks Research upgraded shares of Haleon from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 19th. Morgan Stanley reissued an "overweight" rating on shares of Haleon in a report on Thursday, August 6th. Finally, Jefferies Financial Group restated a "buy" rating on shares of Haleon in a research report on Monday, August 24th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy".

Haleon Stock Up 2.1%

Shares of NYSE:HLN opened at $9.39 on Tuesday. The firm has a market cap of $41.28 billion, a P/E ratio of 24.07, a P/E/G ratio of 2.05 and a beta of 0.12. Haleon PLC Sponsored ADR has a 12-month low of $8.65 and a 12-month high of $11.28. The business has a fifty day simple moving average of $9.85 and a 200 day simple moving average of $9.67. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38.

Haleon Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, September 17th. Stockholders of record on Friday, August 14th will be given a dividend of $0.0642 per share. This represents a dividend yield of 132.0%. The ex-dividend date is Friday, August 14th. Haleon's dividend payout ratio (DPR) is 30.77%.

Haleon Company Profile

Haleon plc NYSE: HLN is a global consumer healthcare company that develops, manufactures and markets products for everyday health and wellness needs. Its portfolio spans oral health, pain relief, respiratory health, vitamins and supplements, digestive health, and therapeutic skin care.

Haleon's well-known brands include Sensodyne, Polident, parodontax, Voltaren, Panadol, Advil, Centrum, Emergen-C, Theraflu, Otrivin, Calpol, ChapStick and Excedrin. The company sells its products through pharmacies, supermarkets, mass retailers, e-commerce platforms and other healthcare channels.

Haleon was formed through the demerger of GSK's consumer healthcare business and became an independent company in 2022.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.